S797
Clinical - Lung
ESTRO 2026
and from 2016-2025 (cohort B).Local control (LC) was defined as the absence of radiological progression. If progression was indeterminate, PET-CT and biopsy were performed to confirm local recurrence. PFS and
OS were calculated from diagnosis date till progression or death, whichever is earlier,
respectively. Kaplan-Meier method was used to calculate survival outcomes. Chi-square test and independent T-test were used to compare variables between the two cohorts. Log-rank test was used to compare the survival between the two cohorts. Results: A total of 90 patients with biopsy-proven NSCLC, majority males (79%) with adenocarcinoma (57%), were included. The median age was 68 years (range,46-88); peripheral tumours were 49 (54.4%), central 21 (23.3%), and ultra-central 20 (22.2%). Baseline cohort-wise characteristics are outlined in Tables 1 and 2. In cohort B (2016-2025), more patients with T1 stage, good PS with no comorbidities, and peripherally located were referred for SBRT. Additionally, patients had smaller target volumes, received a higher median total dose and BED, and had lower Lung-PTV doses.At a median follow-up of 65 months, 5-year LC was 89.2% (81.5% – 96.7%), and 5- year PFS was 48% (35.4% – 63.6%). The median OS was 30 months with 3 and 5-year OS of 45% and 22%, respectively. Local recurrence was seen in 7 patients, and they received salvage systemic therapy. Acute ≤ grade 2 pneumonitis was seen in 17.7% and late ≤ grade 2 in 21% patients. No acute skin and oesophageal toxicity observed. Late chest wall toxicity was seen in 5 patients.
Conclusion: SBRT for ES-NSCLC has demonstrated excellent local control rates with minimal toxicities. This study highlighted a learning curve with SBRT resulting in increased referrals, higher dose delivery, and improved outcomes over the last 15 years. References: 1. Onishi H, Shirato H, Nagata Y, Hiraoka M et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi- institutional study. J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100.2. Chang JY, Mehran RJ, Feng L et al STARS Lung Cancer Trials Group. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single- arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 Oct;22(10):1448-1457. Keywords: SBRT, Non-Small Cell Lung Cancer, Early Stage Dedalus trial: update of sequential chemo-RT- durvalumab, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen Jessica Saddi 1 , Francesco Agustoni 2,3 , Diego Luigi Cortinovis 4,5 , Stefano Arcangeli 6,7 , Luca Sala 5 , Catherine Klersy 8 , Valeria Musella 8 , Giulia Galli 2 , Sabrina Borgetto 2 , Giulia Maria Stella 3,9 , Daniela Cicognini 2 , Elisabetta Bonzano 1 , Andrea Lancia 1 , Salvatore La Mattina 1 , Alessandra Ferrari 2 , Paolo Pedrazzoli 2,3 , Francesco Grossi 10 , Andrea Riccardo Filippi 11,12 1 Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 2 Department of Oncology, Comprehensive Cancer Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 3 Department of Mini-Oral 2625
Made with FlippingBook - Share PDF online